These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 26729494

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS.
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS, Moland ES.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [Abstract] [Full Text] [Related]

  • 29. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T, Kanazawa S, Hara T, Izawa M, Sato T, Yamaguchi T, Tsuji M, Maki H.
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [Abstract] [Full Text] [Related]

  • 30. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
    Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4134-8. PubMed ID: 23774429
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
    Xiao AJ, Miller BW, Huntington JA, Nicolau DP.
    J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
    MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
    Maseda E, Aguilar L, Gimenez MJ, Gilsanz F.
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
    [Abstract] [Full Text] [Related]

  • 39. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
    Robin F, Krebs M, Delmas J, Gibold L, Mirande C, Bonnet R.
    J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.